Consistent with these findings, analysis of a single-cell dataset of melanoma cells obtained from patients prior to BRAFi treatment33 showed a high AR signature score in tumor cell populations characterized by an “elevated AXL program” and low scores in other cell populations (Supplementary Fig. 6d). Here, AXL is linked to melanoma.